Results are presented which show that the Ames TDA tm phenytoin kit may be used with a shortened incubation time (5 minutes) and that, using a Fluorostatv» instrument, a single calibration curve can be stored and used effectively over a three-week period. The importance of temperature control when using a single calibration curve is emphasised. An unexplained finding was that higher results were obtained for phenytoin concentrations up to about 15 mgjl with increasing incubation temperature. There was acceptable precision of measurement at all levels of phenytoin concentration, and there was no significant interference by haemoglobin, bilirubin, or lipids. The TDA results correlated well with those obtained using liquid chromatography (y=O·39 + O·98x, r=O'98, where y=TDA and x=HPLC) and enzyme immunoassay (y=O·08+0·93x, r=O'96, where y=TDA and x=EIA).
should be constructed for each assay run. This was thought not to be the most economical use of reagent, and investigations were instituted to establish the optimum time and temperature of incubation as well as the stability of a single calibration curve over a three-week period.
Ames TDA phenytoin kits (lot number 2061) were supplied by Ames Division, Miles Laboratories Ltd, Slough, England. Each kit contained antibody/ enzyme reagent, phenytoin fluorogenic drug reagent, five calibrators, and concentrated buffer which required dilution (l in 20) in distilled water before use. Kits of the same lot number were used throughout and were stored at +4°C when not in use. The principle of assay is competitive binding between phenytoin in the serum sample and a galactosylumbelliferylphenytoin conjugate for binding sites on the antibody. This labelled drug has little native fluorescence until the galactosyl moiety-is removed by the action of~-galactosidase present in the antibody/enzyme reagent. Labelled drug bound by antibody is unavailable as a substrate for the enzyme. Thus, when phenytoin in the sample displaces labelled phenytoin from antibody binding sites, a fluorescence is obtained, the intensity of which is proportional to the concentration of phenytoin in the 274 *Present address: Biochemistry Department, East Glarnorgan General Hospital, Church Village, Mid Glamorgan.
The usefulness of phenytoin (5,5-diphenylhydantoin) in the control of epilepsy is now well established.' 2 A problem with this drug is that it has a narrow therapeutic range which has been defined as 10-20 mg/1. 3 Plasma phenytoin levels below 10 mg/l may result in poor seizure control while there is an increased incidence of toxic effects at levels greater than 20 mg/l," Additionally, the plasma levels achieved for a given dosage vary from patient to patient. 3 These problems make it desirable to monitor the plasma phenytoin levels so that dosage may be tailored to attain an optimal concentration ofthe drug in blood.
A number of methods for the measurement of phenytoin have been described. These include radioimmunoassay.! gas-liquid chromatography,5 liquid chromatography," and enzyme-immunoassay. 7 A substrate-labelled fluorescence immunoassay technique has been described" and is commercially available as the Ames TDA tm phenytoin kit.
The recommended procedure for use of this kit involves an incubation step lasting 20 minutes. It was considered that, for clinical use, a shorter incubation period of 5-10 minutes would be more acceptable; investigations were undertaken, therefore, to validate the use of the shorter incubation time.
The manufacturers suggest that a calibration curve test serum. All dilutions of samples and additions of reagents were made with the Ames diluter. All fluorescence measurements were performed using a computer-based, ratio-recording, filter fluorimeter (excitation 405 nm, emission 450 nm) (Fluorostat 1m, Ames Division, Miles Laboratories Ltd). This instrument is microprocessor-controlled and uses a pulsed Xenon lamp as the excitation light source. Each fluorescence reading is made during a series of light-dark cycles, each lasting a second, the number of which may be set by the operator. During the first half of the cycle the Xenon lamp is pulsed. It is then switched off for the second half of each cycle. This enables compensation to be made for photomultiplier dark current, stray light, and instrumental noise.
Ratio recording is used to correct for variations in the intensity of the light emitted by the Xenon lamp. The intensity of the excitation light is measured by diverting a proportion of it to a reference photomultiplier. The intensity of the light emitted by fluorescence is measured by the sample photomultiplier and expressed as a ratio of the intensity of the excitation light measured by the reference photomultiplier.
The Fluorostat instrument has an interactive keyboard which enables assay parameters to be entered and stored in the computer memory. The fluorescence values for each calibrator are also stored and used to calculate the results. A permanent copy of the assay parameters and results is provided by an integral electrosensitive strip recorder.
The instrument has the capacity to store a calibration curve for use in subsequent assays after controlratio correction of fluorescence values. Control-ratio correction allows fluorescence values to be corrected for any change in the fluorescence of the top calibrator.
The disposable polystyrene fluorimetry cuvettes were obtained from Walter Sarstedt (UK) Ltd, Leicester, England. Cuvettes were incubated in a dry block immersed in a constant temperature water bath.
Five serum controls were used. Controls I and 5 were Ortho bilevel anticonvulsant/antiasthmatic control (Ortho Diagnostics Ltd, High Wycombe, England) reconstituted according to the manufacturer's instructions with double-deionised water. Controls 2, 3, and 4 were prepared by the addition of 5,5-diphenylhydantoin (sodium salt; Sigma (London) Chemical Co, Poole, England) to phenytoin-free pooled human serum to give concentrations of 3, 13, and 23 mg/1. All controls were stored at -20°C.
Ames TDA assays were set up according to the manufacturer's instructions. Thus, all reagents were allowed to reach room temperature before use. Triplicate aliquots of calibrators, controls or patient samples (50 fL!) were each diluted in assay buffer (2500 fL!). Assay buffer was warmed to assay temperature (20, 25 or" 30°C). Portions (50 fL!) of the diluted calibrators, controls, and patient samples were dispensed with a volume of assay buffer (500 fL!) to cuvettes containing antibody/enzyme reagent (50 fL!) and assay buffer (500 ul), The reaction was started by the addition to each cuvette of the fluorogenic drug reagent (50 fLO dispensed in assay buffer (500 fLl) at I5-second intervals. The fluorescence in each cuvette was measured five, 10, and 20 minutes after addition ofthe labelled drug.
Nine series of assays were performed, over a three-week testing period, at each of three temperatures (20, 25, and 30°C). The top calibrator (30 mg/I) and the five controls were assayed on each occasion. Calibration curves were constructed for only the first, fifth, and ninth assay runs.
The phenytoin concentration of each control was calculated from the calibration curve obtained on the first day of assay, using the 'control-ratio' correction facility of the Fluorostat, which is shown below:
100 measured
Corrected fluorescence = CR x fluorescence io) Fn 00 where CR (control ratio =Fl x I (Fn-efluorescence of top calibrator from assay run n; Fl = fluorescence of top calibrator from assay run 1) The 'corrected' fluorescence value was used to obtain the concentration from the assay-run 1 calibration curve.
Results

CURVE STABILITY
The variations observed over a three-week period between the three calibration curves constructed at 30°C with a five-minute incubation period are shown in Fig. 1 , where each point is the mean of triplicate fluorescence readings. Control ratio correction of the calibration curves obtained from assay runs 5 and 9 relative to the top calibrator of assay-run I decreased the differences between the three curves ( Fig. 2) . Control ratio correction of the time and temperature matched calibration curves at 20°C and 25°C, and at each of the three incubation times, had a similar effect.
The 'corrected' fluorescence values for each calibrator from the three calibration curves, matched for incubation time and temperature, were averaged, and the resulting fluorescence values are expressed prepared with an incubation time of five minutes at 20 c e, 25 D e, and 30 D e were plotted against drug concentration ( Fig. 4) and show a variation in calibration curve shape with alterations in incubation as a percentage of the mean fluorescence value of the top calibrator (30 mgfl) for that curve. These 'normalised' fluorescence values for the calibrators from assays performed at 30 D e at each of the three incubation times are plotted against phenytoin concentration in Fig. 3 and demonstrate that differences in incubation time do not affect the shape of the curves. Similar results were obtained for 'normalised' curves with each of the three incubation times at both 20 D e and 25 D e.
'Normalised' mean fluorescence values for the calibrators derived from the calibration curves PhenytOin (mgIII Fig. 3 Mean calibration curves (from assay runs 1, 5, and 9), each normalised as a percentage of the 30 mg]! calibrator for incubation times of5 (.),10 (.), and 20 ('V ) minutes at 30 cC. Error bars representing one standard deviation either side of the mean are shown for the fiveminute curve. Similar errors were obtained for the other incubation times. Where an error bar falls within the symbol marking the point, it is omitted. temperature. A similar effect was noted for 'normalised' curves for assays incubated for 10 and 20 minutes.
CONTROL VALUES
The phenytoin concentrations in the controls were calculated using control ratio correction from the time and temperature matched calibration curve constructed on the first day of assay.
The different incubation times had no effect on the measured concentration of phenytoin, but an increase in temperature did produce an increase in the apparent phenytoin concentration (Fig. 5 ).
There was no discernible drift in the measured phenytoin concentrations found in the controls over the three-week test period. This is shown in Fig. 6 where the phenytoin concentration measured in each control, with an assay temperature of 30°C and incubation times of five and 20 minutes, are plotted for each assay. Each point is the mean of triplicate observations. CORRELATION Fifty-three plasma samples from epileptic patients who had been prescribed phenytoin were assayed for phenytoin by three methods in current use in our i _ j__~_ l l i::::::::::::a Fig. 6 Daily control values. Phenytoin COIlcentrations (mgll) obtained for each control on each day of assay calculated from the assay run 1 calibration curve constructed using five-minute ( "') and 20-minute (.) incubation periods at 30°e. Each vertical bar represents aile standard deviation either side of the mean of triplicate readings. laboratory: liquid chromatography, enzyme-immunoassay, and Ames TDA. The enzyme-immunoassay system used was EMIT tm (Syva Diagnostics UK Ltd, Maidenhead Berks, England), and the manufacturer's protocol was followed. The fluorescence immunoassay was performed at 30 0 e and incubated variously for 5, 10, or 20 minutes.
The results of the TDA assay were compared with those using liquid chromatographic and enzymeimmunoassay methods. The phenytoin content of the patients' samples ranged from 0 to 33 mg/l with a mean of 13· 1 mgjl as determined by liquid chromatography. The linear regression equations and correlation coefficients for 5-and 20-minute incubations of TDA are given in Table 1 . Similar regressions and correlations were obtained when a lO-minute incubation was used.
INTERFERENCE BY HAEMOGLOBIN, BILIRUBIN, AND LIPAEMIA
Three pools were made of icteric, lipaernic, and haemolysed plasma from patients taking no anticonvulsants. Dilutions were made of the 'abnormal' plasma pools using a non-icteric, non-lipaernic, non-haemolysed plasma containing no anticonvul- 
Davis and Marks sants to give 'low', 'medium', and 'high' levels of the potential interfering substances, ie bilirubin, fat, and haemoglobin. Phenytoin was added to portions of these 'abnormal' plasmas and to a portion of the plasma used for dilution, to give samples with phenytoin concentrations of 0, 5, and 20 mg/l. The prepared samples were analysed for phenytoin using the five-minute TDA assay at 30 0 e and also by liquid chromatography. The results are shown in Table 2 .
Discussion
The calibration curve prepared from the TDA reagents is stable enough for use with the Fluorostat instrument over a three-week period provided that control ratio correction is used (Figs 1 and 2) . The differences between the 'normalised' curves shown in Fig. 4 emphasise, however, the need for accurate and stable temperature control throughout the period of curve storage. The precision of measurement was acceptable, from a clinical standpoint, for all of the controls and analytically acceptable for all of them except the lowest (3 !Jog/ml) for which coefficients of variation of 11-14 %were recorded. The poor precision in this case can be explained by two facts. Firstly, the phenytoin concentration in this control is barely three times the limit of detection claimed by the manufacturers, and, secondly, the largest differences between the corrected calibration curves are between the blank and 5 !Jog/I calibrators (Fig. 2) .
The mean measured phenytoin concentrations of the three lowest controls were significantly different when different incubation temperatures were used (p<0·05, t test between means"), It is doubtful if this would ever be clinically important, however, since the greatest difference recorded was still only equivalent to 1·3 mg/I, The interference study, which was carried out at 30 o e, showed recoveries of 80-90 % of the added phenytoin at the 5 mg/l Ievel. It may be predicted that, in view of the effect of temperature on results (Fig. 5) , even lower recoveries would be observed if lower assay temperatures were used.
None of the incubation times under test (5 and 10 minutes) gave significantly different results from those obtained when the recommended incubation time of 20 minutes was used. The five-minute incubation TDA assay correlated equally as well with the other two methods as did the 10-and 20-minute assays. There seems to be no reason,therefore, why the 5-minute assay should not be used in practice if this is more convenient for the operator. One obvious disadvantage of a five-minute incubation period is that only nine samples or controls can be analysed in one assay run, even when using a stored calibration curve and duplicate analysis.
The lack of interference with the assay result by lipaemia, haemolysis, and icterus is almost certainly due to extensive dilution (1/1683) of the plasma sample before analysis.
The results of this study suggest that the TDA phenytoin assay can be used with a shortened incubation time of five minutes without loss of accuracy or precision and that calibration curves may be stored in the Fluorostat instrument for immediate use at any time over a three-week period. This facility, plus the ability to use a shortened incubation period, makes the TDA assay amenable to use in an outpatient clinic or the 'stat' situation.
